8 studies found for:    Canavan Disease
Show Display Options
RSS Create an RSS feed from your search for:
Canavan Disease
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Suspended Lithium and Acetate for Canavan Disease
Conditions: Canavan Disease;   Infantile;   Deficiency Disease;   Aspartoacylase;   Leukodystrophy, Spongiform
Intervention: Drug: Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
2 Unknown  GTA-Glyceryltriacetate for Canavan Disease
Conditions: Infantile Canavan Disease;   Deficiency Disease, Aspartoacylase
Intervention: Drug: GTA: Glyceryltriacetate
3 Unknown  Oral Glyceryl Triacetate (GTA) in Newborns With Canavan
Condition: Canavan Disease
Interventions: Dietary Supplement: GTA (Glyceryl triacetate);   Drug: GTA glyceryl triacetate
4 Recruiting Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent.
Conditions: Tay Sachs Disease;   Canavan Disease;   Familial Dysautonomia
Intervention: Other: Online pre-test genetic education tool
5 Terminated ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
Conditions: Inherited Metabolic Diseases;   Lysosomal Storage Disorders;   Peroxisomal Storage Diseases;   Inborn Errors of Metabolism;   Mucopolysaccharidosis
Intervention: Biological: ALD-101
6 Recruiting Is the Short Physical Performance Battery a Useful Outcome Measure in Chronic Obstructive Pulmonary Disease
Conditions: Pulmonary Disease, Chronic Obstructive;   Lung Diseases, Obstructive;   Pulmonary Emphysema;   Bronchitis, Chronic;   Lung Diseases;   Disease Progression
Intervention:
7 Not yet recruiting Low Dose IL-2 for Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Interleukin-2 (aldesleukin).
8 Recruiting The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab
Condition: Osteoporosis Treatment
Interventions: Drug: 18 months teriparatide followed by 18 months denosumab;   Drug: three separate 6 month cycles of daily teriparatide, each followed by one of denosumab

Indicates status has not been verified in more than two years